Abstract
Background
Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling older adults living in Australia and the USA.
Methods
We analysed baseline data from 19,114 participants, over 70 years of age (over 65 years of age, if from an ethnic minority). The association of self-reported statin use and prevalence of depressive symptoms, as measured by a validated depression scale [Center for Epidemiological Studies Depression Scale (CES-D 10)], was determined using logistic regression models. Multivariable logistic models were implemented to account for important demographics and other lifestyle and socioeconomic factors, such as sex, age, living status, education and smoking history.
Results
A total of 5987 individuals were statin users. Of those, 633 (10.6%) had depressive symptoms (CES-D 10 cut-off ≥ 8), compared with 1246 (9.5%) of the non-statin users. In the unadjusted model, statin use was associated with an increase in prevalence of depressive symptoms (odds ratio 1.13, confidence interval 1.02–1.25, p = 0.02). However, after adjusting for important demographic and socioeconomic factors, the use of statins was not significantly associated with depressive symptoms (odds ratio 1.09, confidence interval 0.98–1.20, p = 0.11). In secondary analyses, only simvastatin was marginally associated with an increased prevalence of depressive symptoms. Statins were associated with a decreased prevalence of depressive symptoms in individuals with severe obesity (body mass index > 35 kg/m2) and an increased prevalence in participants between 75 and 84 years of age.
Conclusion
This study in a large community-dwelling older population did not show any association of statins with late-life depressive symptoms, after accounting for important socioeconomic and demographic factors. Confounding by indication is an important issue to be addressed in future pharmacoepidemiologic studies of statins.
Similar content being viewed by others
References
Arokiasamy P, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? BMC Med. 2015;13(1):1–16.
World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017. p. 1–24.
Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.
Bakunina N, Pariante CM, Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology. 2015;144(3):365–73.
You H, Lu W, Zhao S, Hu Z, Zhang J. The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother. 2013;14(11):1467–76.
Williams LJ, et al. Statin and aspirin use and the risk of mood disorders among men. Int J Neuropsychopharmacol. 2016;19(6):1–4.
Salagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord. 2016;200:235–42.
Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X. Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry. 2014;14:438.
Mandas A, et al. Cognitive decline and depressive symptoms in late-life are associated with statin use: evidence from a population-based study of Sardinian old people living in their own home. Neurol Res. 2014;36(3):247–54.
Tuccori M, et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs. 2014;28(3):249–72.
Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410.
Dave CV, Winterstein AG, Park H, Cook RL, Hartzema AG. Comparative risk of lipophilic and hydrophilic statins on incident depression: a retrospective cohort study. J Affect Disord. 2018;238:542–6.
Glaus J, et al. Aspirin and statin use and the subsequent development of depression in men and women: results from a longitudinal population-based study. J Affect Disord. 2015;182:126–31.
Bulbulia R, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013–20.
Collins R, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.
Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71(1):85–94.
Ruscica M, Macchi C, Pavanello C, Corsini A, Sahebkar A, Sirtori CR. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018;50:33–40.
Waters DD. Meta-analyses of statin trials: clear benefit for primary prevention in the elderly. J Am Coll Cardiol. 2013;62(22):2100–1.
Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med. 2018;379(16):1572–4.
McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379:1519–28.
McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509–18.
Grimm R, et al. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36(2):555–64.
Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1993;10(2):77–84.
Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): a systematic review with meta-analysis. PLoS One. 2016;11(5):1–17.
Mohebbi M, et al. Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults. Gen Hosp Psychiatry. 2018;51:118–25.
Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult. Arch Intern Med. 1999;159:1701–4.
Cheng ST, Chan ACM. The Center for Epidemiologic Studies Depression Scale in older Chinese: thresholds for long and short forms. Int J Geriatr Psychiatry. 2005;20(5):465–70.
Alberti KGM, Zimmet P, Shaw J. The IDF consensus worldwide definition of the metabolic syndrome. Brussels Int Diabetes Fed. 2006;23(5):469–80.
Otte C, et al. Major depressive disorder. Nat Rev Dis Prim. 2016;2:16065.
Delgado I, et al. Depressive symptoms in obesity: relative contribution of low-grade inflammation and metabolic health. Psychoneuroendocrinology. 2018;91:55–61.
Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens. 2015;28(11):1295–302.
De Jonge P, Roy JF, Saz P, Marcos G, Lobo A. Prevalent and incident depression in community-dwelling elderly persons with diabetes mellitus: results from the ZARADEMP project. Diabetologia. 2006;49(11):2627–33.
Bagherniya M, et al. Metabolic syndrome and its components are related to psychological disorders: a population based study. Diabetes Metab Syndr Clin Res Rev. 2017;11:S561–6.
Mulvahill JS, et al. Effect of metabolic syndrome on late-life depression: associations with disease severity and treatment resistance. J Am Geriatr Soc. 2017;65(12):2651–8.
Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA. 2018;319(22):2289.
Agustini B, Berk M. Medications with depression as an adverse effect. JAMA. 2018;320(17):1815.
Friis RH, Sellers TA. Experimental study designs. Epidemiol Public Health Pract. 2009;275(6):327–60.
Köhler-Forsberg O, Gasse C, Petersen L, Nierenberg AA, Mors O, Østergaard SD. Statin treatment and the risk of depression. J Affect Disord. 2019;246:706–15.
Mansi I, Frei CR, Pugh MJ, Mortensen EM. Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy. 2013;33(6):615–26.
Schaakxs R, Comijs HC, Lamers F, Kok RM, Beekman ATF, Penninx BWJH. Articles associations between age and the course of major depressive disorder: a 2-year longitudinal cohort study. Lancet Psychiatry. 2018;366(18):1–10.
Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18(9):963–74.
Geerlings MI, Gerritsen L. Late-life depression, hippocampal volumes, and hypothalamic-pituitary-adrenal axis regulation: a systematic review and meta-analysis. Biol Psychiatry. 2017;82(5):339–50.
Liang Feng TPN, Yap KB, Kua E. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol Drug Saf. 2010;19:942–8.
Bornstein SR, Schuppenies A, Wong M-L, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Mol Psychiatry. 2006;11(10):892–902.
Raison CL, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry. 2013;70(1):31–41.
Köhler O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. JAMA Psychiatry. 2014;71(12):1381–91.
McFarland AJ, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 2014;15(11):20607–37.
Davison KM, Kaplan BJ. Lipophilic statin use and suicidal ideation in a sample of adults with mood disorders. Crisis. 2014;35(4):278–82.
Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis. 2016;58(5):514–28.
Acknowledgements
The authors acknowledge the efforts of research personnel and the long-term involvement of participants of the ASPREE study.
Author information
Authors and Affiliations
Consortia
Contributions
JJM, RLW, MRN, RCS, CMR and JEL contributed to the design of the original ASPREE randomised controlled trial. MB, RLW, MRN, RCS, CMR, AT, CB, JEL, MM and JJM contributed to the design of the ASPREE-D sub-study. All authors actively participated in designing the current study. BA and MM performed the data analysis. BA drafted the manuscript that has been read, edited and approved by all co-authors.
Corresponding author
Ethics declarations
Funding
The study is supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (Grant No. U01AG029824), the National Health and Medical Research Council of Australia (Grant Nos. 334047, 1127060), Monash University (Australia) and the Victorian Cancer Agency (Australia). Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (APP1059660 and APP1156072) and Christopher M. Reid is supported by a NHMRC Senior Research Fellowship (APP1045862).
Conflict of interest
Bruno Agustini, Mohammadreza Mohebbi, Robyn L. Woods, John J. McNeil, Mark R. Nelson, Raj C. Shah, Anne M. Murray, Michael E. Ernst, Christopher M. Reid, Andrew Tonkin, Jessica E. Lockery and Michael Berk have not conflicts of interest that are directly relevant to the content of this article.
Ethics approval
The ASPREE study was conducted in accordance with the Declaration of Helsinki 1964 as revised in 2008, the NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law and the International Conference of Harmonisation Guidelines for Good Clinical Practice. ASPREE also follows the Code of Federal Regulations as it relates to areas of clinical research.
Additional information
ASPREE Investigator Group listed on www.aspree.org.
Rights and permissions
About this article
Cite this article
Agustini, B., Mohebbi, M., Woods, R.L. et al. Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. CNS Drugs 33, 685–694 (2019). https://doi.org/10.1007/s40263-019-00633-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-019-00633-3